(Q44604172)

English

Pefloxacin and vancomycin vs. gentamicin, colistin sulphate and vancomycin for prevention of infections in granulocytopenic patients: a randomised double-blind study

scientific article published on January 1, 1991

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Pefloxacin and vancomycin vs. gentamicin, colistin sulphate and vancomycin for prevention of infections in granulocytopenic patients: a randomised double-blind study (English)

1 reference

10.1016/0277-5379(91)90481-R

https://api.crossref.org/works/10.1016/0277-5379(91)90481-R

3 December 2022

0 references

1 reference

based on heuristic

inferred from title

1 reference

10.1016/0277-5379(91)90481-R

https://api.crossref.org/works/10.1016/0277-5379(91)90481-R

3 December 2022

author name string

E. Archimbaud

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1827284

3 December 2022

D. Guyotat

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1827284

3 December 2022

J. Maupas

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1827284

3 December 2022

C. Ploton

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1827284

3 December 2022

A. Nageotte

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1827284

3 December 2022

Y. Devaux

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1827284

3 December 2022

X. Thomas

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1827284

3 December 2022

J. Fleurette

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1827284

3 December 2022

D. Fiere

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1827284

3 December 2022

language of work or name

1 reference

National Center for Biotechnology Information

PubMed publication ID

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=1827284

3 December 2022

publication date

1 January 1991

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

full work available at URL

https://api.elsevier.com/content/article/PII:027753799190481R?httpAccept=text/xml

1 reference

10.1016/0277-5379(91)90481-R

https://api.crossref.org/works/10.1016/0277-5379(91)90481-R

3 December 2022

https://api.elsevier.com/content/article/PII:027753799190481R?httpAccept=text/plain

1 reference

10.1016/0277-5379(91)90481-R

https://api.crossref.org/works/10.1016/0277-5379(91)90481-R

3 December 2022

European Journal of Cancer

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

27

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

174-178

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Approaching the controversies in antibacterial management of cancer patients

1

1 reference

10.1016/0277-5379(91)90481-R

https://api.crossref.org/works/10.1016/0277-5379(91)90481-R

3 December 2022

Cytosine arabinoside induced gastrointestinal toxic alterations in sequential chemotherapeutic protocols: a clinical-pathologic study of 33 patients

2

1 reference

10.1016/0277-5379(91)90481-R

https://api.crossref.org/works/10.1016/0277-5379(91)90481-R

3 December 2022

The new fluorinated quinolones for infection prevention in acute leukemia

4

1 reference

10.1016/0277-5379(91)90481-R

https://api.crossref.org/works/10.1016/0277-5379(91)90481-R

3 December 2022

Long-term use of quinolones and their safety

5

1 reference

10.1016/0277-5379(91)90481-R

https://api.crossref.org/works/10.1016/0277-5379(91)90481-R

3 December 2022

Impact of fluoroquinolones on the gastrointestinal flora

6

1 reference

10.1016/0277-5379(91)90481-R

https://api.crossref.org/works/10.1016/0277-5379(91)90481-R

3 December 2022

Norfloxacin versus vancomycin/polymyxin for prevention of infections in granulocytopenic patients

8

1 reference

10.1016/0277-5379(91)90481-R

https://api.crossref.org/works/10.1016/0277-5379(91)90481-R

3 December 2022

Norfloxacin for prevention of bacterial infections in granulocytopenic patients

9

1 reference

10.1016/0277-5379(91)90481-R

https://api.crossref.org/works/10.1016/0277-5379(91)90481-R

3 December 2022

Infection prophylaxis in acute leukemia: a comparison of ciprofloxacin with trimethoprim-sulfamethoxazole and colistin.

11

1 reference

10.1016/0277-5379(91)90481-R

https://api.crossref.org/works/10.1016/0277-5379(91)90481-R

3 December 2022

Ofloxacin for prevention of bacterial infections in granulocytopenic patients.

12

1 reference

10.1016/0277-5379(91)90481-R

https://api.crossref.org/works/10.1016/0277-5379(91)90481-R

3 December 2022

Ofloxacin versus vancomycin/polymyxin for prevention of infections in granulocytopenic patients

13

1 reference

10.1016/0277-5379(91)90481-R

https://api.crossref.org/works/10.1016/0277-5379(91)90481-R

3 December 2022

The comparative pharmacokinetics of five quinolones

14

1 reference

10.1016/0277-5379(91)90481-R

https://api.crossref.org/works/10.1016/0277-5379(91)90481-R

3 December 2022

Pharmacokinetics and clinical results of parenterally administered new quinolones in humans

15

1 reference

10.1016/0277-5379(91)90481-R

https://api.crossref.org/works/10.1016/0277-5379(91)90481-R

3 December 2022

[Pharmacokinetic behavior of pefloxacin in man]

16

1 reference

10.1016/0277-5379(91)90481-R

https://api.crossref.org/works/10.1016/0277-5379(91)90481-R

3 December 2022

A laboratory assessment of ciprofloxacin and comparable antimicrobial agents

18

1 reference

10.1016/0277-5379(91)90481-R

https://api.crossref.org/works/10.1016/0277-5379(91)90481-R

3 December 2022

A randomized trial of oral vancomycin in neutropenic patients

19

1 reference

10.1016/0277-5379(91)90481-R

https://api.crossref.org/works/10.1016/0277-5379(91)90481-R

3 December 2022

A comparison of trimethoprim-sulfamethoxazole plus nystatin with gentamicin plus nystatin in the prevention of infections in acute leukemia

20

1 reference

10.1016/0277-5379(91)90481-R

https://api.crossref.org/works/10.1016/0277-5379(91)90481-R

3 December 2022

Identifiers

10.1016/0277-5379(91)90481-R

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44604172&oldid=1783695219"